Sichuan Kelun Pharmaceutical Co Ltd002422
± MixedCapitalrelevance
Interim report shows revenue decline but positive net profit and cash flow; mixed financial results.
Impact on assets 1
Others
Sichuan Kelun Pharmaceutical Co LtdKelun Pharmaceutical released its 2026 interim report, with total operating revenue of 8.839 billion yuan, down 2.70% from the same period last year, and net profit attributable to the parent company of 1.128 billion yuan. Net cash inflow from operating activities was 2.341 billion yuan, the asset-liability ratio was 28.11%, the gross margin was 47.57%, and diluted earnings per share was 0.71 yuan. The company had 38,400 shareholders, and the top ten shareholders held 41.57% of the total share capital.
Sichuan Kelun Pharmaceutical Co LtdInterim report shows revenue decline but positive net profit and cash flow; mixed financial results.